GlobeNewswire·Oct 20, 2025, 4:00 PM ET

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Purple Biotech Ltd. received a notification from Nasdaq on October 16, 2025, stating it is non-compliant with the minimum $1.00 bid price requirement for 30 consecutive trading days.
The company has 180 calendar days until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for ten consecutive business days.
The notification has no immediate effect on the trading of Purple Biotech ADSs under the symbol "PPBT" on the Nasdaq Capital Market or its listing on the Tel Aviv Stock Exchange.
If compliance is not met by April 14, 2026, the company may be eligible for an additional 180-day cure period if it meets other listing standards including market value of publicly held shares.
Failure to cure the deficiency within the second period could result in a delisting notice, which the company may appeal to a Nasdaq hearings panel.
Purple Biotech intends to monitor its ADS price & may consider options to cure the deficiency, including potentially changing the ratio between its ADSs & ordinary shares.
The company is a clinical-stage developer of first-in-class therapies for tumor immune evasion & drug resistance, with a pipeline including CAPTN-3, CM24, NT219, IM1240, & IM1305.